FindTrial
Sign In

Comparison of conventional quadruple therapy and high-dose dual therapy for HP eradication

Comparison of conventional quadruple therapy and high-dose dual therapy for HP eradication

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056895
Enrollment
Unknown
Registered
2022-02-22
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Group 1:Conventional quadruple therapy
Group 2:High-dose dual therapy

Sponsors

Third People's Hospital of Jingdezhen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. HP-positive untreated patients; 2. Aged 18-75 years, no gender limit.

Exclusion criteria

Exclusion criteria: 1. Previous anti-HP therapy; 2. Contraindications to the study drugs or allergies to the study drugs; 3. Severe organ dysfunction, severe or unstable cardiopulmonary disease or endocrine disease; 4. Pregnant and lactating patients; 5. Patients undergoing upper gastrointestinal surgery; 6. Patients with a history of malignant tumors; 7. Refusal to sign an informed consent form.

Design outcomes

Primary

MeasureTime frame
Helicobacter pylori eradication rate;—

Secondary

MeasureTime frame
Overall incidence of adverse events;Symptom improvement rate;Patient compliance;Cost benefit ratio;—

Countries

China

Contacts

Public ContactYang Li
yanglijdz@sina.com+86 13607983780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026